Physician profile
Joann E Johnson
NPI 1104809508
$2,176.11
in general payments reported to CMS, 2019-2025
15 companies · $434 in 2025
The $434 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $124 · 2021: $234 · 2022: $277 · 2023: $518 · 2024: $417 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.77 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $575.52 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $358.90 | 2021-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $276.40 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Pfizer INC. | $206.54 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $155.76 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $143.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $93.41 | 2019-2023 | M-M-R II, Vaxelis, Vaxneuvance |
| Ironshore Pharmaceuticals INC. | $89.21 | 2019-2024 | Jornay Pm |
| Seqirus USA INC | $62.78 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Adlon Therapeutics L.P. | $55.07 | 2020-2021 | |
| Abbvie INC. | $51.51 | 2020-2022 | |
| Phadia US INC. | $37.49 | 2023-2025 | Immunocap |
| Neos Therapeutics, Lp | $36.31 | 2022 | |
| Tris Pharma INC | $20.09 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.